What 4 Analyst Ratings Have To Say About Ambrx Biopharma
Portfolio Pulse from Benzinga Insights
Ambrx Biopharma (NASDAQ:AMAM) has received 2 somewhat bullish and 2 indifferent analyst ratings in the last quarter. The average 12-month price target for the stock is $12.25, up 145% from the previous average of $5.00.
May 19, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ambrx Biopharma has 2 somewhat bullish and 2 indifferent analyst ratings, with an average 12-month price target of $12.25, a 145% increase from the previous average.
The mixed analyst ratings for Ambrx Biopharma indicate uncertainty in the stock's short-term performance. The average 12-month price target has increased significantly, but the presence of both bullish and indifferent ratings suggests that the stock's direction is not clear. As a result, the short-term impact on the stock price is neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100